Botulax® (Letybo) – Botulinum Toxin Type A [South Korea]

Botulax® (Letybo) – Botulinum Toxin Type A | Refined for Research Use from South Korea

Product Overview

Botulax®, internationally known as Letybo in certain markets, is a Botulinum Toxin Type A developed and manufactured by Hugel, Inc., one of South Korea’s premier biopharmaceutical companies. With a highly purified composition and consistent potency, Botulax® is widely used in research settings to investigate neuromuscular inhibition, facial muscle modulation, and the molecular mechanisms of wrinkle formation.

While Letybo is authorized for therapeutic and cosmetic use in select global markets, the version offered here is intended strictly for Research Use Only (RUO) and is not for human or veterinary use. Researchers value Botulax® for its reliability, controlled diffusion, and cost-effective positioning when compared to other Botulinum Toxin A analogs such as Botox® or Xeomin®.

---

Key Features & Advantages

• ✅ Manufactured by Hugel, Inc. – South Korea
  Produced in GMP-certified facilities ensuring pharmaceutical-grade quality.

• ✅ High Purity Formulation
  Low bacterial protein load and consistent molecular activity enhance experimental accuracy.

• ✅ Fast Onset & Stable Duration
  Results typically begin to appear within 2–3 days and may last 3–4 months in neuromuscular models.

• ✅ Balanced Diffusion Profile
  Ideal for controlled studies involving facial muscle dynamics or localized nerve inhibition.

• ✅ Recognized Globally as Letybo®
  Exported to multiple international markets and gaining popularity as a competitive Botulinum A product.

---

Product Specifications

• Product Name: Botulax® (Letybo) – Botulinum Toxin Type A

• Active Ingredient: Clostridium botulinum toxin type A

• Form: Lyophilized powder

• Packaging: 100 Units / vial

• Appearance: White to off-white powder; clear solution upon reconstitution

• Origin: South Korea

• Manufacturer: Hugel, Inc.

• Storage Conditions: Store at 2°C–8°C; reconstituted solution should be used within 24 hours

• Use Classification: Research Use Only (RUO) – not for human use, cosmetic treatment, or therapeutic application

---

How It Works – Mechanism of Action

Botulax® (Letybo) operates by blocking the release of acetylcholine at the neuromuscular junction, resulting in temporary muscle paralysis in the targeted area. Upon administration, the botulinum toxin binds specifically to presynaptic cholinergic nerve terminals. It enters the neuron through endocytosis and releases its light chain into the cytoplasm, where it cleaves SNAP-25—a key SNARE protein essential for acetylcholine vesicle fusion.

This biochemical interruption prevents acetylcholine release, thereby halting the signal transmission to muscle fibers. In research, this property makes Botulax® particularly valuable for exploring muscular relaxation, neuromodulatory pathways, and aesthetic effect modeling. Its molecular consistency also supports reproducibility in comparative toxin studies and pharmacological profiling.

For foundational research, see PubMed articles on Botulinum Toxin A mechanisms.

---

Applications in Research

• Facial muscle activity inhibition and symmetry modeling

• Wrinkle formation and anti-aging pathways

• Neurotransmitter blockade and nerve-muscle signal transmission

• Chronic migraine or hyperhidrosis modeling

• Comparative efficacy studies among botulinum toxins

---

Compliance Statement

This product is manufactured in South Korea by Hugel, Inc. and is officially exported for non-clinical, laboratory-based research purposes only. It is not intended for human injection, medical treatment, or cosmetic use. All users must comply with local regulatory requirements regarding the storage, handling, and use of botulinum toxin for research.

---

Tags / Keywords

Botulax, Letybo, Botulinum Toxin Type A, Hugel Inc., Korean Botulinum, Neuromodulator Research, RUO Toxin, Aesthetic Toxin Research, Anti-aging Mechanism Studies, Research Grade Botulinum, SNAP-25, Muscle Relaxant Research

---

Relevant External References

• Hugel, Inc. Official Website

• Letybo EMA Approval News (2023)

• Botulinum Toxin A – Mechanism on PubMed